ORGOVYX

Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022

Retrieved on: 
Thursday, January 26, 2023
Research, Prostate cancer, Food, Gonadotropin-releasing hormone, USPI, Scott Richter, Endometriosis, Hart–Scott–Rodino Antitrust Improvements Act, History, Sale, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, SG, Roivant Sciences, SPIRIT, ORGOVYX, New Drug Application, EMA, Woman, RWS, Shanda, United Kingdom, Type 2, TRX, Richter, Pain, Safety, PDUFA, R, NYSE, Type, Risk, European Medicines Agency, Calendar, Patient, Growth, Uterine fibroid, German–Soviet Commercial Agreement (1940), Leuprorelin, Video game, Fine chemical, Credit, Security (finance), Pharmaceutical industry, Health insurance, Medical imaging, Airline, Takeda, Accord, Pfizer

Third fiscal quarter 2022 net product revenues for ORGOVYX in the U.S. were $48.7 million, reflecting 12% sequential growth compared to the second fiscal quarter 2022.

Key Points: 
  • Third fiscal quarter 2022 net product revenues for ORGOVYX in the U.S. were $48.7 million, reflecting 12% sequential growth compared to the second fiscal quarter 2022.
  • Approximately 4,000 new patients started treatment with ORGOVYX in the third fiscal quarter of 2022, reaching approximately 26,000 cumulative patients since launch.
  • In December 2022, Myovant completed a New Drug Submission to Health Canada seeking marketing approval for ORGOVYX for advanced prostate cancer.
  • Third fiscal quarter 2022 net product revenues for MYFEMBREE in the U.S. were $10.5 million, reflecting 64% sequential growth compared to second fiscal quarter 2022.

Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer

Retrieved on: 
Thursday, December 15, 2022
Woman, Roivant Sciences, ORGOVYX, SAN, Endometriosis, Hospital, Marketing, University of California, San Diego Performance-Based Skills Assessment, Science, Prostate, Faculty, Medivation, Toxic shock syndrome, Neoplasm, Endocrinology, MD, Yale New Haven Hospital, Internal medicine, History, University, COVID-19, Uterine fibroid, Patient, Metabolism, Management, Pharmaceutical industry, Lyell
Key Points: 

    Sumitovant Biopharma, Sumitomo Pharma, and Myovant Sciences Enter into Definitive Agreement

    Retrieved on: 
    Monday, October 24, 2022
    Slate, Skadden, Reading, CEO, Pediatrics, ORGOVYX, Communication, Roivant Sciences, THE, NYSE, AND, Report of the Special Committee on the Termination of the National Emergency, Company, Committee, FDA, Risk, New, Growth, Woman, Hand, Annual general meeting, Oliver Cromwell, Board, Prostate cancer, Goldman Sachs, Schedule, Sullivan & Cromwell, U.S. Securities and Exchange Commission, SEC, Schedule 13D, Sumitomo Mitsui Banking Corporation, Patient, Biotechnology, Man, Urology, Acquisition, Health, Form, Forward-looking statement, COVID-19, Security (finance), Fine chemical, Pharmaceutical industry, Management

    NEW YORK and BASEL, Switzerland and OSAKA, Japan, Oct. 23, 2022 /PRNewswire/ -- Sumitovant Biopharma Ltd. ("Sumitovant"), in conjunction with parent company Sumitomo Pharma Co., Ltd. ("Sumitomo Pharma"), and Myovant Sciences ("Myovant") (NYSE: MYOV) announced today that they have entered into a definitive agreement pursuant to which Sumitovant will acquire all outstanding shares of Myovant not already owned by Sumitovant for $27.00 per share in cash. This corresponds to a total transaction value of $1.7 billion on a fully diluted basis, and a total company value of $2.9 billion on a fully diluted basis. Sumitovant currently beneficially owns 52% of the issued and outstanding shares of Myovant as more particularly described in Sumitovant's Schedule 13D/A filed with the U.S. Securities and Exchange Commission (the "SEC").

    Key Points: 
    • NEW YORK and BASEL, Switzerland and OSAKA, Japan, Oct. 23, 2022 /PRNewswire/ -- Sumitovant Biopharma Ltd. ("Sumitovant"), in conjunction with parent company Sumitomo Pharma Co., Ltd. ("Sumitomo Pharma"), and Myovant Sciences ("Myovant") (NYSE: MYOV) announced today that they have entered into a definitive agreement pursuant to which Sumitovant will acquire all outstanding shares of Myovant not already owned by Sumitovant for $27.00 per share in cash.
    • "We are pleased to have reached an agreement with Sumitovant and Sumitomo Pharma that recognizes the remarkable success Myovant has achieved," said David Marek, CEO of Myovant.
    • This communication contains forward-looking statements, including statements regarding expectations about the proposed transaction involving Myovant, Sumitovant and Sumitomo Pharma.
    • Myovant, Sumitovant and Sumitomo Pharma disclaim any obligation to update these forward-looking statements, except as may be required.

    Brand Institute Partners on Brand Name Development for European Commission Approved Treatment for Advanced Hormone-Sensitive Prostate Cancer

    Retrieved on: 
    Friday, June 17, 2022
    Name, Review, FDA, Food and Drug Administration, European Medicines Agency, Safety, Union, World, WHO, C.E.O, Roivant Sciences, American Medical Association, Health Canada, Approximation error, Brand Institute, AMA, World Health Organization, European Commission, Adult, Food, HC, EMA, Patient, ORGOVYX, EC, Pharmaceutical industry

    ORGOVYXwas developed by Myovant Sciences and is the first and only oral androgen deprivation therapy available in Europe for the treatment of advanced hormone-sensitive prostate cancer.

    Key Points: 
    • ORGOVYXwas developed by Myovant Sciences and is the first and only oral androgen deprivation therapy available in Europe for the treatment of advanced hormone-sensitive prostate cancer.
    • The European Commission (EC) has granted marketing authorization for ORGOVYX in all member states of the European Union, Iceland, Lichtenstein, and Norway.
    • ORGOVYX received U.S. Food and Drug Administration (FDA) approval for the treatment of adult patients with advanced prostate cancer in December 2020.
    • "The entire Brand Institute and Drug Safety Institute team congratulates Myovant Sciences on the EC approval for ORGOVYX," said Brand Institute's Chairman and C.E.O., James L. Dettore.

    ORGOVYX® (relugolix) Now Available from Onco360 for the Treatment of Adult Patients with Advanced Prostate Cancer

    Retrieved on: 
    Monday, June 6, 2022
    Oncology, Health, General Health, Radiology, Pharmaceutical, Biotechnology, Gonadotropin-releasing hormone, Death, Adult, ORGOVYX, Roivant Sciences, Prostate cancer, Food, United, Relugolix, Disease, National Cancer Institute, FDA, Male, Patient, Program, Hospital, SEER, Oncology, Pfizer, Diagnosis, Journal of Oncology Pharmacy Practice, PharMerica, Specialty pharmacy, Regulation of tobacco by the U.S. Food and Drug Administration, Malignancy, Cancer, Pharmaceutical industry, Medical imaging, Epidemiology

    Onco360 is honored to become a specialty pharmacy provider for ORGOVYX patients, said Benito Fernandez, Chief Commercial Officer, Onco360.

    Key Points: 
    • Onco360 is honored to become a specialty pharmacy provider for ORGOVYX patients, said Benito Fernandez, Chief Commercial Officer, Onco360.
    • We are committed to supporting the highly specialized needs of patients battling advanced prostate cancer across the United States.
    • Prostate cancer is the most commonly diagnosed cancer in male patients.
    • Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers.

    Myovant Sciences Announces Preliminary Financial Results for Third Quarter of Fiscal Year 2021

    Retrieved on: 
    Monday, January 10, 2022
    Infertility, Pain, Man, LinkedIn, Gonadotropin-releasing hormone, FDA, Health care, Webcast, Roivant Sciences, Total, New Drug Application, European Commission, Female, Pregnancy, Union, Private Securities Litigation Reform Act, Medication, Woman, Norethisterone, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Adoption, SEC, Gedeon Richter, Endometriosis, Patient, Uterine fibroid, Food, Therapy, NYSE, Risk, Twitter, GLOBE, Royal commission, ORGOVYX, Sumitomo Dainippon Pharma, Growth, Testosterone, Marketing, Conference, Adult, Relugolix, Review, Prostate cancer, U.S. Securities and Exchange Commission, Fossil fuel, Pharmaceutical industry, Fine chemical, Audit, Pfizer

    Furthermore, this press release includes information regarding Myovant Sciences preliminary financial results for the third fiscal quarter ended December 31, 2021.

    Key Points: 
    • Furthermore, this press release includes information regarding Myovant Sciences preliminary financial results for the third fiscal quarter ended December 31, 2021.
    • Myovant Sciences is currently in the process of finalizing its financial results for the third fiscal quarter ended December 31, 2021, and the preliminary financial results presented in this press release are based only on preliminary information available to Myovant Sciences as of January 10, 2022.
    • These preliminary financial results should not be viewed as a substitute for audited consolidated financial statements prepared in accordance with U.S. GAAP, and undue reliance should not be placed on Myovant Sciences preliminary financial results.
    • Myovant Sciences independent registered public accounting firm has not audited or reviewed the preliminary financial results included in this press release or expressed any opinion or other form of assurance on such preliminary financial results.

    Spirovant to Present SP-101 Data at the 2021 North American Cystic Fibrosis Conference

    Retrieved on: 
    Thursday, October 28, 2021
    Inhalation, Sumitomo Dainippon Pharma, Cystic fibrosis, Tropism, CFTR, Patient, FDA, NYSE, Degenerative disease, ORGOVYX, Conference, Uterine fibroid, CF, Cystic fibrosis transmembrane conductance regulator, Overactive bladder, AAV, Pharmaceutical industry, Fine chemical

    W05.5: Delivery of SP-101 restores CFTR function in human CF airway epithelial cultures and drives hCFTRΔR transgene expression in the airways of ferretsNovember 3, 2021, 11:00 AM - 1:00 PM ET Presenter: Katherine Excoffon, Ph.D., VP, Research, Spirovant Sciences Presented During: W05--PTC-GMS: Approaches for Delivery of Nucleotide Based Therapeutics

    Key Points: 
    • PHILADELPHIA, Oct. 28, 2021 /PRNewswire/ -- Spirovant Sciences , a gene therapy company developing treatments and cures for inherited respiratory diseases including cystic fibrosis (CF), todayannounced that it will be delivering oral and poster presentations highlighting pre-clinical data for its compound, SP-101, at the 2021 North American Cystic Fibrosis Conference (NACFC 2021), November 2-5.
    • Spirovant is a gene therapy company focused on changing the course of cystic fibrosis and other respiratory diseases.
    • The company's current investigational gene therapy technologies are designed to overcome the historical barriers that have prevented effective genetic treatments for cystic fibrosis.
    • Spirovant's lead programs are in development for cystic fibrosis.